Sort
51,593 grants matching “hepatitis”
New Approaches To Passive Immunoprophylaxis
$776,756Robert H. Purcell · Niaid Extramural Activities · Z01 · FY2007 · AI
Warfarin Pharmacogenetics in Pediatric Patients
$776,687Ronald N Hines · Medical College Of Wisconsin · R01 · FY2009 · HD
At the Intersection of HIV and COVID-19: Medicaid Data as a Complement to Cohort Studies
$776,684Bryan Lau · Johns Hopkins University · R01 · FY2024 · AI
Next generation quantitative HCV drug resistance assay
$776,646Richard Wagner · Medosome Biotec, Llc · R44 · FY2022 · DK
Risk Factors for AIDS among Persons Who Inject Drugs: HIV and COVID-19
$776,533Don C Des Jarlais · New York University · R01 · FY2022 · DA
Point-of-care Nucleic Acid Amplification Test for pangenomic Hepatitis C diagnosis in outpatient clinics
$776,510Jonathan D Posner · University Of Washington · R01 · FY2024 · AI
Human factors-designed triple test for HIV, HBV, and HCV infection in whole blood using target amplification, signal amplification, and crumpled graphene biosensor readout
$776,341Brian T. Cunningham · University Of Illinois At Urbana-Champaign · R01 · FY2025 · AI
New retroviral restriction factor
$776,245Tatyana V. Golovkina · University Of Chicago · R56 · FY2021 · AI
Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network: Nonin
$776,222Nathan M Bass · University Of California, San Francisco · U01 · FY2010 · DK
Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV Therapy
$776,106Vincent Lo Re · University Of Pennsylvania · R01 · FY2022 · AI
Alcohol Metabolism, Functional Consequences and Apoptosis Signaling Mechanism
$776,088Byoung-Joon Song · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2011 · AA
Glucagon-mediated glycemic effect in humans with and without rerouted gut after bariatric surgery
$775,865Marzieh Salehi · University Of Texas Hlth Science Center · R01 · FY2025 · DK
A Rhesus Macaque Model of HIV and HBV co-infection
$775,817Benjamin J Burwitz · Oregon Health & Science University · R01 · FY2022 · AI
A NOVEL STRATEGY TO INHIBIT SARS-COV-2 INFECTION AND COVID-19
$775,538Philippe Andre Gallay · Scripps Research Institute, The · R01 · FY2024 · AI
Molecular Basis of Cancer Virus Replication, Transformation, and Innate Defense
$775,523Daniel Dimaio · Yale University · P01 · FY2015 · CA
Mid Southern Primary Care Networks Node
$775,477Li-Tzy T Wu · Duke University · UG1 · FY2016 · DA
Women and Infants Transmission Study IV
$775,351University Of Illinois At Chicago · U01 · FY2001 · AI
Characterization of Genomics and Metabolomics among Individuals Highly-Exposed, but resistant to Mtb Infection
$775,211Neel Rajnikant Gandhi · Emory University · R01 · FY2021 · AI
Human population based genetic studies to elucidate the biology of NAFLD
$775,142Elizabeth K Speliotes · University Of Michigan At Ann Arbor · R01 · FY2016 · DK
IMMUNE REGULATION AND VACCINE DEVELOPMENT IN LEISHMANIASIS
$775,112David Sacks · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Modeling HIV/AIDS Associated Neurological Disorders with Human Pluripotent Cells
$775,000Tariq M Rana · University Of California, San Diego · DP1 · FY2018 · DA
RSV and SARS Coronavirus Pathogenesis
$775,000Barney Scott Graham · Niaid Extramural Activities · Z01 · FY2007 · AI
Modeling HIV/AIDS Associated Neurological Disorders with Human Pluripotent Cells
$775,000Tariq M Rana · University Of California, San Diego · DP1 · FY2017 · DA
Modeling HIV/AIDS Associated Neurological Disorders with Human Pluripotent Cells
$775,000Tariq M Rana · University Of California, San Diego · DP1 · FY2020 · DA
Modeling HIV/AIDS Associated Neurological Disorders with Human Pluripotent Cells
$775,000Tariq M Rana · University Of California, San Diego · DP1 · FY2015 · DA